Evotec SE

NASDAQ:EVO

Drug Manufacturers - Specialty & Generic

Healthcare
$1.46 -0.57%

-$0.02 today

Market cap
$518.56M
Beta
1.30
P/E (TTM)
-4.2
EPS (TTM)
-$1.09
52W Low $2.31High $4.42

Volume 0.04M

Average 0.08M

EVO Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

Evotec SENASDAQ: EVO

Income Tax Expense · Q1 FY2026 · quarter ended Mar 2026

Income tax expense turns negative

Q1 FY2026 income tax expense was -€248.01K, compared with €1.73M a year earlier. Trailing-twelve-month income tax expense was €14.64M.

Context

  • Income tax expense amounted to 3.2% of revenue in FY2025, up 2.9 pp from a year earlier.
  • Income tax expense increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income tax expense holds near -€248.01K or moves back toward the trailing-twelve-month quarterly average of €3.66M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-€248.01K-101.7% QoQ
Last fiscal yearDec 2025
-€23.88M-1236.1% YoY
LTMMar 2026
€14.64M-49.5% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-114.4%——
1 year-1236.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Tax Expense history

EUR · from the income statement

Latest · FY2025
(23.88M) EUR
Year-over-year change
-1236.1%

Income Tax Expense vs competitors

How EVO compares with its peers on the latest reported figures

  • Peers report in different currencies, so income tax expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -49.5% is the 8th highest of 11, against a peer median of +67.1%.
  • Income tax expense amounts to 2.0% of revenue for EVO, versus a peer median of 1.1%.
EVO Competitors
Income Tax Expense for EVO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALVOAlvotechLTM Mar 2026$124.64M USD+2682.2%—22.3%
EVOEvotec SELTM Mar 2026€14.64M EUR-49.5%—2.0%
PCRXPacira BioSciences, Inc.LTM Mar 2026$8.03M USD-77.5%—1.1%
AZTAAzenta, Inc.LTM Sep 2026$6.86M USD+122.1%—1.1%
HROWHarrow Health, Inc.LTM Mar 2026$3.8M USD+2257.8%+257.1%1.4%
PHVSPharvaris N.V.LTM Sep 2026€2.76M EUR+67.6%+43.1%—
SDGRSchrödinger, Inc.LTM Sep 2026$2.4M USD+66.5%+146.1%0.9%
SYRESpyre Therapeutics, Inc.LTM Sep 2026$0 USD+100.0%—0.0%
NVCRNovoCure LimitedLTM Mar 2026-$2.17M USD-106.3%—0.3%
TDOCTeladoc Health, Inc.LTM Mar 2026-$13.96M USD-4.5%—0.6%
TLRYTilray Brands, Inc.LTM Feb 2026-$167.21M USD-424.7%—14.1%
Peer median (excluding EVO) —+67.1%+146.1%1.1%

Competitors are the stored peer set for EVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue618.03M751.45M781.43M796.97M757.26M
Cost of Revenue466.49M577.38M606.38M682.09M694.6M
Gross Profit151.54M174.07M175.05M114.88M62.66M
Gross Margin24.5%23.2%22.4%14.4%8.3%
Research & Development65.7M76.64M68.53M50.86M74.33M
Selling, General & Admin105.45M156.19M169.61M188.2M123.65M
Operating Expenses110.55M153.22M222.56M257.4M197.97M
Depreciation & Amortization70.4M83.2M92.98M101.62M95.55M
EBITDA316.63M(57.61M)24.13M(80.66M)(13.89M)
EBITDA Margin51.2%-7.7%3.1%-10.1%-1.8%
Operating Income41M20.85M(47.51M)(142.52M)(135.31M)
Operating Margin6.6%2.8%-6.1%-17.9%-17.9%
Interest Income2.27M8.34M9.26M2.44M4.25M
Interest Expense9.25M13.15M11.74M11.7M13.87M
Other Income / Expenses195.98M(174.81M)(33.09M)(51.46M)12M
Income Before Tax236.98M(153.96M)(80.59M)(193.98M)(123.31M)
Pre-Tax Margin38.3%-20.5%-10.3%-24.3%-16.3%
Income Tax Expense21.47M21.7M3.32M2.1M(23.88M)
Net Income215.51M(175.66M)(83.91M)(196.08M)(99.43M)
Net Margin34.9%-23.4%-10.7%-24.6%-13.1%
EPS (Basic)0.65(0.49)(0.23)(0.56)(0.28)
EPS (Diluted)0.65(0.49)(0.23)(0.56)(0.28)
Weighted Avg Shares332.81M353.35M353.87M353.29M355.16M
Weighted Avg Shares (Diluted)332.81M353.41M353.87M354.59M355.16M

Evotec SE

NASDAQ:EVO

Intrinsic Alpha fair value

Locked

Current Price

$1.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.